A Phase I Study of Idarubicin Dose Escalation for Remission Induction Therapy in Acute Myeloid Leukemia

被引：0
|
作者：
Lee, Mark [1 ]
Kim, Sung-Yong [1 ]
机构：
[1] Konkuk Univ, Med Ctr, Hematol Oncol, Seoul, South Korea
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase I study of idarubicin dose escalation for remission induction therapy in acute myeloid leukemia
    Lee, Mark Hong
    Kim, Sung-Yong
    LEUKEMIA & LYMPHOMA, 2016, 57 (10) : 2268 - 2274
  • [2] STUDY IN PHASE I/II OF THE ESCALATION OF DOSES OF IDARUBICIN IN THE INDUCTION OF PRIMARY ACUTE MYELOID LEUKEMIA
    Mauri, Brunet S.
    Garrido, A.
    Esteve, J.
    Tormo, M.
    Salamero, O.
    Vives, S.
    Nomdedeu, J.
    Navarro, B.
    Ribera, J. M.
    Diaz-Beya, M.
    Calabuig, M.
    Pratcorona, M.
    Sierra, J.
    HAEMATOLOGICA, 2015, 100 : 146 - 147
  • [3] Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia
    Bradstock, Kenneth F.
    Link, Emma
    Di Iulio, Juliana
    Szer, Jeff
    Marlton, Paula
    Wei, Andrew H.
    Enno, Arno
    Schwarer, Anthony
    Lewis, Ian D.
    D'Rozario, James
    Coyle, Luke
    Cull, Gavin
    Campbell, Phillip
    Leahy, Michael F.
    Hahn, Uwe
    Cannell, Paul
    Tiley, Campbell
    Lowenthal, Ray M.
    Moore, John
    Cartwright, Kimberly
    Cunningham, Ilona
    Taper, John
    Grigg, Andrew
    Roberts, Andrew W.
    Benson, Warwick
    Hertzberg, Mark
    Deveridge, Sandra
    Rowlings, Philip
    Mills, Anthony K.
    Gill, Devinder
    Bardy, Peter
    Campbell, Lynda
    Seymour, John F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (15) : 1678 - 1685
  • [4] A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia
    Lowenthal, RM
    Bradstock, KF
    Matthews, JP
    Bishop, JF
    Juneja, S
    Cobcroft, R
    Eliadis, P
    Enno, A
    Gill, D
    Herrmann, RP
    Manoharan, A
    Page, FJ
    Rooney, KF
    Rosenfeld, D
    Seldon, M
    Taylor, KM
    Wolf, MM
    Young, GAR
    LEUKEMIA & LYMPHOMA, 1999, 34 (5-6) : 501 - 510
  • [5] Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study
    Yue-ying Mao
    Hua-cong Cai
    Kai-ni Shen
    Chang, Long
    Zhang, Lu
    Zhang, Yan
    Feng, Jun
    Wang, Wei
    Yang, Chen
    Tie-nan Zhu
    Ming-hui Duan
    Dao-bin Zhou
    Xin-xin Cao
    Li, Jian
    ANNALS OF HEMATOLOGY, 2022, 101 (04) : 831 - 836
  • [6] Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study
    Yue-ying Mao
    Hua-cong Cai
    Kai-ni Shen
    Long Chang
    Lu Zhang
    Yan Zhang
    Jun Feng
    Wei Wang
    Chen Yang
    Tie-nan Zhu
    Ming-hui Duan
    Dao-bin Zhou
    Xin-xin Cao
    Jian Li
    Annals of Hematology, 2022, 101 : 831 - 836
  • [7] Idarubicin, high-dose cytarabine and etoposide for induction of remission in acute myeloid leukemia.
    Singhal, S
    Powles, R
    Treleaven, J
    Horton, C
    Hamblin, M
    Zomas, A
    Prendiville, J
    Saso, R
    Mackay, H
    Milan, S
    Mehta, J
    BLOOD, 1995, 86 (10) : 2039 - 2039
  • [8] IDARUBICIN, HIGH-DOSE CYTARABINE AND ETOPOSIDE FOR REMISSION INDUCTION IN THERAPY-RELATED ACUTE MYELOID-LEUKEMIA
    PHILPOTT, N
    MEHTA, J
    TRELEAVEN, J
    POWLES, R
    LEUKEMIA & LYMPHOMA, 1994, 15 (1-2) : 127 - 130
  • [9] A phase II study of elacytarabine plus idarubicin as second course remission-induction therapy in patients with acute myeloid leukemia.
    Rizzieri, D.
    Krug, U.
    Schlenk, R. F.
    Vey, N.
    Thomas, X. G.
    Huguet, F.
    Johansen, M.
    Jacobsen, T. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia
    Trifilio, Steven
    Zhou, Zheng
    Mehta, Jayesh
    Czerniak, Colleen
    Pi, Judy
    Greenberg, Deborah
    Koslosky, Molly
    Pantiru, Mihaela
    Altman, Jessica
    LEUKEMIA RESEARCH, 2013, 37 (08) : 868 - 871
12345